Drug intelligence / Profile preview

eflornithine + interferon alpha-2a

Development stage: Discontinued
Lead developer: Mayo Clinic
Modality: Small Molecules, Recombinant Proteins and Enzymes
Administration: Oral, Subcutaneous

Overview

A combination therapy consisting of eflornithine (an irreversible ornithine decarboxylase inhibitor) and interferon alpha-2a (a recombinant interferon). This combination was studied for the treatment of recurrent glioma based on in vitro evidence suggesting synergistic effects between the two agents. Eflornithine works by irreversibly binding to ornithine decarboxylase, reducing cellular polyamine levels, while interferon alpha-2a helps the immune system fight infections and has potential anti-tumor properties.

Other names: DFMO + interferon alpha-2aα-difluoromethylornithine + interferon alpha-2a

Targets

ODC1 (Ornithine decarboxylase)IFNAR (Immune system modulation via type I interferon receptor)

Beyond the preview

Go deeper on eflornithine + interferon alpha-2a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on eflornithine + interferon alpha-2a.